Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DIF-3 is a chemical compound that acts by activating GSK-3β to facilitate the degradation of cyclin D1 and c-Myc, resulting in reduced expression levels of these proteins. In addition, DIF-3 inhibits Wnt/β-catenin signaling pathway-related proteins in DLD-1 cells. This compound exerts a potent antiproliferative effect on the HeLa human cervical cancer cell line by inducing cyclin D1 degradation and inhibiting cyclin D1 mRNA expression [1].
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 955 | 现货 | ||
5 mg | ¥ 2,420 | 现货 | ||
10 mg | ¥ 3,590 | 现货 | ||
25 mg | ¥ 5,830 | 现货 | ||
50 mg | ¥ 7,950 | 现货 | ||
100 mg | ¥ 10,900 | 现货 | ||
500 mg | ¥ 21,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,180 | 现货 |
产品描述 | DIF-3 is a chemical compound that acts by activating GSK-3β to facilitate the degradation of cyclin D1 and c-Myc, resulting in reduced expression levels of these proteins. In addition, DIF-3 inhibits Wnt/β-catenin signaling pathway-related proteins in DLD-1 cells. This compound exerts a potent antiproliferative effect on the HeLa human cervical cancer cell line by inducing cyclin D1 degradation and inhibiting cyclin D1 mRNA expression [1]. |
体外活性 | In this study, we examined the effects of six DIF analogues (DIF-1, DIF-2 (which has pentanone in place of hexanone), DIF-3 (dechlorinated form of DIF-1), 2-MIDIF-1 (2-methoxy isomer of DIF-1), DMPH (dechlorinated form of DIF-3), and THPH (4-hydroxy substitution of DMPH)) on DNA synthesis, cell growth, erythroid differentiation, and cytosolic free calcium concentration ([Ca2+]i) in human leukemia K562 cells. DIF-3 proved to be the most potent anti-leukemic agent among them, and the order of potency for causing growth inhibition, erythroid induction, and increases in [Ca2+]iTHPH in all the categories tested. [1] DIF-3 activates GSK-3beta to accelerate the proteolysis of cyclin D1 and that this mechanism is involved in the DIF-3-induced G(0)/G(1) arrest in mammalian cells.[2] |
分子量 | 272.72 |
分子式 | C13H17ClO4 |
CAS No. | 113411-17-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90.0 mg/mL (330.0 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.6668 mL | 18.3338 mL | 36.6676 mL | 91.6691 mL |
5 mM | 0.7334 mL | 3.6668 mL | 7.3335 mL | 18.3338 mL | |
10 mM | 0.3667 mL | 1.8334 mL | 3.6668 mL | 9.1669 mL | |
20 mM | 0.1833 mL | 0.9167 mL | 1.8334 mL | 4.5835 mL | |
50 mM | 0.0733 mL | 0.3667 mL | 0.7334 mL | 1.8334 mL | |
100 mM | 0.0367 mL | 0.1833 mL | 0.3667 mL | 0.9167 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
DIF-3 113411-17-9 Inhibitor inhibitor inhibit